Enter password to view Website Audit
Analysis
Website
Infermedica
Analysis
Website
Infermedica
Analysis
Website
Infermedica
Published on
2026-03-18
For
Infermedica
Score
45
Infermedica is a Polish digital health company (founded 2012) providing an AI-powered Medical Guidance Platform for symptom triage, patient intake, care navigation, and follow-up — certified as an EU MDR Class IIb medical device. 94% clinical accuracy. 23M+ health checks completed. Used by 100+ healthcare organisations in 30+ countries in 24 languages. Key customers: Allianz, Techniker Krankenkasse, Healthdirect Australia (26M citizens), Microsoft, Sana Kliniken, Médis. 12+ peer-reviewed publications. $45M total funding led by One Peak Partners. 2026 focus: Conversational Triage with LLMs and MDR certification.
Market
AI Medical Guidance / Clinical Decision Support / Digital Triage / Health AI Platform / Patient Navigation
Audience
CISOs, Chief Medical Officers, VP Digital Health, IT Directors, and procurement leads at health insurance companies, hospital systems, government health services, and health technology platforms; developers integrating clinical decision support APIs
HQ
Wrocław, Poland
Website
Performance
36
Social Proof
42
Brand
40
Social Proof
43
Copy
45
Copy
48
Brand
50
SEO
46
Copy
47
Copy
50
Performance
Homepage Returns HTTP 403 to Standard Crawlers
Score
36
Severity
High
Finding
infermedica.com returns a 403 Forbidden error to standard HTTP fetch requests — the third site in this audit series with this pattern after Spryker and Orgvue. The homepage meta description ('Assess your symptoms with our AI-powered tool and receive personalized guidance on your next steps, all in just a few minutes.') is indexed by Google (visible via the organic search snippet), so Googlebot is getting through — but social media scrapers, link preview tools (LinkedIn, WhatsApp, Slack), and standard HTTP client tools all receive 403. For a healthcare AI company whose primary customer acquisition channel is B2B inbound from health system and insurance company procurement teams sharing links in Slack and email, broken link previews are a silent conversion drag.
Recommendation
Whitelist all known social media scraper and search engine bot user-agents at the CDN/WAF layer: LinkedInBot, Slackbot, Twitterbot, WhatsApp, Googlebot, Bingbot. Ensure the homepage serves an Open Graph-tagged 200 response to all bot requests. Verify via Google Search Console URL Inspection that the indexed meta description is current. Test a LinkedIn link preview of infermedica.com to confirm what the card shows when a sales rep shares the homepage URL in a procurement conversation — this is the moment where a blank or broken preview creates an avoidable trust signal failure.
Performance
Homepage Returns HTTP 403 to Standard Crawlers
Score
36
Severity
High
Finding
infermedica.com returns a 403 Forbidden error to standard HTTP fetch requests — the third site in this audit series with this pattern after Spryker and Orgvue. The homepage meta description ('Assess your symptoms with our AI-powered tool and receive personalized guidance on your next steps, all in just a few minutes.') is indexed by Google (visible via the organic search snippet), so Googlebot is getting through — but social media scrapers, link preview tools (LinkedIn, WhatsApp, Slack), and standard HTTP client tools all receive 403. For a healthcare AI company whose primary customer acquisition channel is B2B inbound from health system and insurance company procurement teams sharing links in Slack and email, broken link previews are a silent conversion drag.
Recommendation
Whitelist all known social media scraper and search engine bot user-agents at the CDN/WAF layer: LinkedInBot, Slackbot, Twitterbot, WhatsApp, Googlebot, Bingbot. Ensure the homepage serves an Open Graph-tagged 200 response to all bot requests. Verify via Google Search Console URL Inspection that the indexed meta description is current. Test a LinkedIn link preview of infermedica.com to confirm what the card shows when a sales rep shares the homepage URL in a procurement conversation — this is the moment where a blank or broken preview creates an avoidable trust signal failure.
Performance
Homepage Returns HTTP 403 to Standard Crawlers
Score
36
Severity
High
Finding
infermedica.com returns a 403 Forbidden error to standard HTTP fetch requests — the third site in this audit series with this pattern after Spryker and Orgvue. The homepage meta description ('Assess your symptoms with our AI-powered tool and receive personalized guidance on your next steps, all in just a few minutes.') is indexed by Google (visible via the organic search snippet), so Googlebot is getting through — but social media scrapers, link preview tools (LinkedIn, WhatsApp, Slack), and standard HTTP client tools all receive 403. For a healthcare AI company whose primary customer acquisition channel is B2B inbound from health system and insurance company procurement teams sharing links in Slack and email, broken link previews are a silent conversion drag.
Recommendation
Whitelist all known social media scraper and search engine bot user-agents at the CDN/WAF layer: LinkedInBot, Slackbot, Twitterbot, WhatsApp, Googlebot, Bingbot. Ensure the homepage serves an Open Graph-tagged 200 response to all bot requests. Verify via Google Search Console URL Inspection that the indexed meta description is current. Test a LinkedIn link preview of infermedica.com to confirm what the card shows when a sales rep shares the homepage URL in a procurement conversation — this is the moment where a blank or broken preview creates an avoidable trust signal failure.
Social Proof
Health Checks Count Inconsistency — 12M (blog) vs 23M (GetApp/Capterra) vs 'More Than 15M' (press)
Score
42
Severity
High
Finding
Third-party sources display different health check completion counts for Infermedica across different publications and time periods: the Techniker Krankenkasse blog post mentions '12 million users globally so far'; a 2023 press release states '15 million successful health checks'; GetApp and Capterra profiles state '23 million successful health checks to date.' The homepage search snippet mentions the Schmitt-Thompson clinical comparison study. These figures appear at different timestamps, suggesting the number is genuinely growing — but the most visible third-party listing figure (23M) differs substantially from the most recent blog reference (12M). A procurement manager at a major insurer who researches Infermedica across sources will encounter three different usage scale figures. The most current figure should be the only one visible across all owned channels.
Recommendation
Conduct an audit of all health check count references across the website, third-party listings, press releases, and blog posts. Update all owned channels to the most recent verified figure — if the current count is 23M+, update every mention site-wide including product pages, GetApp/Capterra vendor profiles, and press boilerplate. Establish a quarterly update protocol for all scale claims (health checks, language count, country count, organisation count). The health check figure is Infermedica's primary social proof metric — it should be accurate, consistent, and updated on a schedule so it compounds over time rather than creating confusion.
Social Proof
Health Checks Count Inconsistency — 12M (blog) vs 23M (GetApp/Capterra) vs 'More Than 15M' (press)
Score
42
Severity
High
Finding
Third-party sources display different health check completion counts for Infermedica across different publications and time periods: the Techniker Krankenkasse blog post mentions '12 million users globally so far'; a 2023 press release states '15 million successful health checks'; GetApp and Capterra profiles state '23 million successful health checks to date.' The homepage search snippet mentions the Schmitt-Thompson clinical comparison study. These figures appear at different timestamps, suggesting the number is genuinely growing — but the most visible third-party listing figure (23M) differs substantially from the most recent blog reference (12M). A procurement manager at a major insurer who researches Infermedica across sources will encounter three different usage scale figures. The most current figure should be the only one visible across all owned channels.
Recommendation
Conduct an audit of all health check count references across the website, third-party listings, press releases, and blog posts. Update all owned channels to the most recent verified figure — if the current count is 23M+, update every mention site-wide including product pages, GetApp/Capterra vendor profiles, and press boilerplate. Establish a quarterly update protocol for all scale claims (health checks, language count, country count, organisation count). The health check figure is Infermedica's primary social proof metric — it should be accurate, consistent, and updated on a schedule so it compounds over time rather than creating confusion.
Social Proof
Health Checks Count Inconsistency — 12M (blog) vs 23M (GetApp/Capterra) vs 'More Than 15M' (press)
Score
42
Severity
High
Finding
Third-party sources display different health check completion counts for Infermedica across different publications and time periods: the Techniker Krankenkasse blog post mentions '12 million users globally so far'; a 2023 press release states '15 million successful health checks'; GetApp and Capterra profiles state '23 million successful health checks to date.' The homepage search snippet mentions the Schmitt-Thompson clinical comparison study. These figures appear at different timestamps, suggesting the number is genuinely growing — but the most visible third-party listing figure (23M) differs substantially from the most recent blog reference (12M). A procurement manager at a major insurer who researches Infermedica across sources will encounter three different usage scale figures. The most current figure should be the only one visible across all owned channels.
Recommendation
Conduct an audit of all health check count references across the website, third-party listings, press releases, and blog posts. Update all owned channels to the most recent verified figure — if the current count is 23M+, update every mention site-wide including product pages, GetApp/Capterra vendor profiles, and press boilerplate. Establish a quarterly update protocol for all scale claims (health checks, language count, country count, organisation count). The health check figure is Infermedica's primary social proof metric — it should be accurate, consistent, and updated on a schedule so it compounds over time rather than creating confusion.
Brand
MDR Class IIb Medical Device Certification (2025) — Not Prominently Featured in Homepage Context
Score
40
Severity
High
Finding
Infermedica's Medical Guidance Platform achieved EU MDR Class IIb medical device certification in 2025 — described in the year-in-review blog as 'one of the highest possible levels of compliance for Software as a Medical Device (SaMD) in Europe' and as certification 'reserved for solutions that directly impact patient care—where accurate, reliable guidance is vital to avoid death, long-term disability, or serious health deterioration.' This is a genuinely extraordinary regulatory achievement for a digital health AI platform: no general-purpose AI chatbot or wellness app can claim EU Class IIb. Yet the homepage meta description focuses on symptom checking, and the certification appears only in Capterra/GetApp descriptions and the year-in-review blog. For a product competing for enterprise contracts at major European health systems and insurers, the MDR Class IIb badge is the single most powerful procurement signal available.
Recommendation
Make MDR Class IIb the homepage's centrepiece regulatory trust signal — not buried in a compliance section but in the hero itself: 'The only AI-powered medical triage platform certified as a Class IIb Medical Device under EU MDR.' This claim differentiates Infermedica from every general-purpose AI health assistant that is not a certified medical device. Pair it with the ISO 13485, HIPAA, GDPR, and SOC 2 certifications in a compact trust strip. For the EU healthcare market (insurers, health systems, government health services), the MDR Class IIb badge answers the #1 procurement gate question ('Is this clinically validated and regulatorily compliant?') in a single visible element.
Brand
MDR Class IIb Medical Device Certification (2025) — Not Prominently Featured in Homepage Context
Score
40
Severity
High
Finding
Infermedica's Medical Guidance Platform achieved EU MDR Class IIb medical device certification in 2025 — described in the year-in-review blog as 'one of the highest possible levels of compliance for Software as a Medical Device (SaMD) in Europe' and as certification 'reserved for solutions that directly impact patient care—where accurate, reliable guidance is vital to avoid death, long-term disability, or serious health deterioration.' This is a genuinely extraordinary regulatory achievement for a digital health AI platform: no general-purpose AI chatbot or wellness app can claim EU Class IIb. Yet the homepage meta description focuses on symptom checking, and the certification appears only in Capterra/GetApp descriptions and the year-in-review blog. For a product competing for enterprise contracts at major European health systems and insurers, the MDR Class IIb badge is the single most powerful procurement signal available.
Recommendation
Make MDR Class IIb the homepage's centrepiece regulatory trust signal — not buried in a compliance section but in the hero itself: 'The only AI-powered medical triage platform certified as a Class IIb Medical Device under EU MDR.' This claim differentiates Infermedica from every general-purpose AI health assistant that is not a certified medical device. Pair it with the ISO 13485, HIPAA, GDPR, and SOC 2 certifications in a compact trust strip. For the EU healthcare market (insurers, health systems, government health services), the MDR Class IIb badge answers the #1 procurement gate question ('Is this clinically validated and regulatorily compliant?') in a single visible element.
Brand
MDR Class IIb Medical Device Certification (2025) — Not Prominently Featured in Homepage Context
Score
40
Severity
High
Finding
Infermedica's Medical Guidance Platform achieved EU MDR Class IIb medical device certification in 2025 — described in the year-in-review blog as 'one of the highest possible levels of compliance for Software as a Medical Device (SaMD) in Europe' and as certification 'reserved for solutions that directly impact patient care—where accurate, reliable guidance is vital to avoid death, long-term disability, or serious health deterioration.' This is a genuinely extraordinary regulatory achievement for a digital health AI platform: no general-purpose AI chatbot or wellness app can claim EU Class IIb. Yet the homepage meta description focuses on symptom checking, and the certification appears only in Capterra/GetApp descriptions and the year-in-review blog. For a product competing for enterprise contracts at major European health systems and insurers, the MDR Class IIb badge is the single most powerful procurement signal available.
Recommendation
Make MDR Class IIb the homepage's centrepiece regulatory trust signal — not buried in a compliance section but in the hero itself: 'The only AI-powered medical triage platform certified as a Class IIb Medical Device under EU MDR.' This claim differentiates Infermedica from every general-purpose AI health assistant that is not a certified medical device. Pair it with the ISO 13485, HIPAA, GDPR, and SOC 2 certifications in a compact trust strip. For the EU healthcare market (insurers, health systems, government health services), the MDR Class IIb badge answers the #1 procurement gate question ('Is this clinically validated and regulatorily compliant?') in a single visible element.
Social Proof
Mayo Clinic Proceedings Peer-Reviewed Study (January 2026) — Not Surfaced on Homepage
Score
43
Severity
Medium
Finding
In January 2026, peer-reviewed research published in Mayo Clinic Proceedings demonstrated the clinical impact of Infermedica's AI triage in the Healthdirect Australia implementation — including 'a marked reduction in emergency care intent and stronger alignment of patients' care-seeking behavior with actual clinical acuity.' A paper in Mayo Clinic Proceedings is among the most prestigious medical journal publications available: it provides the clinical validation credibility that distinguishes Infermedica from the dozens of wellness apps and AI chatbots claiming health guidance capability. Yet this January 2026 publication — from two months ago — is mentioned only in a blog post update on the Healthdirect case study page, not on the homepage.
Recommendation
Add the Mayo Clinic Proceedings citation to the homepage as a clinical validation proof point: 'Published in Mayo Clinic Proceedings — Infermedica's AI triage significantly reduces emergency care intent' with a link to the study or the case study page. For a B2B medical AI platform, a peer-reviewed publication in a top-tier medical journal is more persuasive than any analyst ranking or award badge. Pair it with the 'Journal of Hospital Administration' and 'Frontiers in Public Health' citations that the homepage search snippet already references: 'Validated in Mayo Clinic Proceedings, Journal of Hospital Administration, and Frontiers in Public Health — 12+ peer-reviewed publications.'
Social Proof
Mayo Clinic Proceedings Peer-Reviewed Study (January 2026) — Not Surfaced on Homepage
Score
43
Severity
Medium
Finding
In January 2026, peer-reviewed research published in Mayo Clinic Proceedings demonstrated the clinical impact of Infermedica's AI triage in the Healthdirect Australia implementation — including 'a marked reduction in emergency care intent and stronger alignment of patients' care-seeking behavior with actual clinical acuity.' A paper in Mayo Clinic Proceedings is among the most prestigious medical journal publications available: it provides the clinical validation credibility that distinguishes Infermedica from the dozens of wellness apps and AI chatbots claiming health guidance capability. Yet this January 2026 publication — from two months ago — is mentioned only in a blog post update on the Healthdirect case study page, not on the homepage.
Recommendation
Add the Mayo Clinic Proceedings citation to the homepage as a clinical validation proof point: 'Published in Mayo Clinic Proceedings — Infermedica's AI triage significantly reduces emergency care intent' with a link to the study or the case study page. For a B2B medical AI platform, a peer-reviewed publication in a top-tier medical journal is more persuasive than any analyst ranking or award badge. Pair it with the 'Journal of Hospital Administration' and 'Frontiers in Public Health' citations that the homepage search snippet already references: 'Validated in Mayo Clinic Proceedings, Journal of Hospital Administration, and Frontiers in Public Health — 12+ peer-reviewed publications.'
Social Proof
Mayo Clinic Proceedings Peer-Reviewed Study (January 2026) — Not Surfaced on Homepage
Score
43
Severity
Medium
Finding
In January 2026, peer-reviewed research published in Mayo Clinic Proceedings demonstrated the clinical impact of Infermedica's AI triage in the Healthdirect Australia implementation — including 'a marked reduction in emergency care intent and stronger alignment of patients' care-seeking behavior with actual clinical acuity.' A paper in Mayo Clinic Proceedings is among the most prestigious medical journal publications available: it provides the clinical validation credibility that distinguishes Infermedica from the dozens of wellness apps and AI chatbots claiming health guidance capability. Yet this January 2026 publication — from two months ago — is mentioned only in a blog post update on the Healthdirect case study page, not on the homepage.
Recommendation
Add the Mayo Clinic Proceedings citation to the homepage as a clinical validation proof point: 'Published in Mayo Clinic Proceedings — Infermedica's AI triage significantly reduces emergency care intent' with a link to the study or the case study page. For a B2B medical AI platform, a peer-reviewed publication in a top-tier medical journal is more persuasive than any analyst ranking or award badge. Pair it with the 'Journal of Hospital Administration' and 'Frontiers in Public Health' citations that the homepage search snippet already references: 'Validated in Mayo Clinic Proceedings, Journal of Hospital Administration, and Frontiers in Public Health — 12+ peer-reviewed publications.'
Copy
Healthdirect Australia (26 Million Citizens) — Most Powerful Customer Story Likely Understated on Homepage
Score
45
Severity
Medium
Finding
Infermedica's collaboration with Healthdirect Australia is arguably the most impressive government-scale healthcare deployment of AI triage in the world: a single implementation serving up to 26 million Australian citizens through both a nurse advice helpline and a public-facing symptom checker, with half of emergency calls diverted to less acute services and 44,000 patients connected to virtual emergency departments in one year. This is population-scale clinical impact evidence. The homepage search snippet shows the Journal of Hospital Administration comparison citation, but the Healthdirect scale figures ('26 million citizens', 'half of emergency calls diverted') are the kind of proof that would headline a press release at most health tech companies. These figures — sourced from peer-reviewed research, not marketing — belong prominently on the homepage.
Recommendation
Build a 'Customer Impact' section on the homepage featuring the Healthdirect Australia case with the key metrics: '26 million Australians served · 50% of emergency calls redirected to appropriate care · Published in Mayo Clinic Proceedings.' This represents the clearest, most externally validated evidence of clinical and operational impact in Infermedica's portfolio. Complement it with the Techniker Krankenkasse results (86% member satisfaction, 76% follow recommendation compliance) and the Médis data (22% of members changed care intent after using virtual triage). These are not marketing claims — they are independently measured clinical outcomes. They belong on the homepage, not buried in case study blog posts.
Copy
Healthdirect Australia (26 Million Citizens) — Most Powerful Customer Story Likely Understated on Homepage
Score
45
Severity
Medium
Finding
Infermedica's collaboration with Healthdirect Australia is arguably the most impressive government-scale healthcare deployment of AI triage in the world: a single implementation serving up to 26 million Australian citizens through both a nurse advice helpline and a public-facing symptom checker, with half of emergency calls diverted to less acute services and 44,000 patients connected to virtual emergency departments in one year. This is population-scale clinical impact evidence. The homepage search snippet shows the Journal of Hospital Administration comparison citation, but the Healthdirect scale figures ('26 million citizens', 'half of emergency calls diverted') are the kind of proof that would headline a press release at most health tech companies. These figures — sourced from peer-reviewed research, not marketing — belong prominently on the homepage.
Recommendation
Build a 'Customer Impact' section on the homepage featuring the Healthdirect Australia case with the key metrics: '26 million Australians served · 50% of emergency calls redirected to appropriate care · Published in Mayo Clinic Proceedings.' This represents the clearest, most externally validated evidence of clinical and operational impact in Infermedica's portfolio. Complement it with the Techniker Krankenkasse results (86% member satisfaction, 76% follow recommendation compliance) and the Médis data (22% of members changed care intent after using virtual triage). These are not marketing claims — they are independently measured clinical outcomes. They belong on the homepage, not buried in case study blog posts.
Copy
Healthdirect Australia (26 Million Citizens) — Most Powerful Customer Story Likely Understated on Homepage
Score
45
Severity
Medium
Finding
Infermedica's collaboration with Healthdirect Australia is arguably the most impressive government-scale healthcare deployment of AI triage in the world: a single implementation serving up to 26 million Australian citizens through both a nurse advice helpline and a public-facing symptom checker, with half of emergency calls diverted to less acute services and 44,000 patients connected to virtual emergency departments in one year. This is population-scale clinical impact evidence. The homepage search snippet shows the Journal of Hospital Administration comparison citation, but the Healthdirect scale figures ('26 million citizens', 'half of emergency calls diverted') are the kind of proof that would headline a press release at most health tech companies. These figures — sourced from peer-reviewed research, not marketing — belong prominently on the homepage.
Recommendation
Build a 'Customer Impact' section on the homepage featuring the Healthdirect Australia case with the key metrics: '26 million Australians served · 50% of emergency calls redirected to appropriate care · Published in Mayo Clinic Proceedings.' This represents the clearest, most externally validated evidence of clinical and operational impact in Infermedica's portfolio. Complement it with the Techniker Krankenkasse results (86% member satisfaction, 76% follow recommendation compliance) and the Médis data (22% of members changed care intent after using virtual triage). These are not marketing claims — they are independently measured clinical outcomes. They belong on the homepage, not buried in case study blog posts.
Copy
Competitor Context — 'Performed as Safely as Schmitt-Thompson' Citation on Homepage, Not Explained
Score
48
Severity
Medium
Finding
The homepage indexed snippet includes the quote: 'In our evaluation, Infermedica performed as safely as Schmitt-Thompson. Additionally, Infermedica collects more initial patient symptoms, allowing for more data-driven assistance. — The Journal of Hospital Administration.' This citation is powerful — Schmitt-Thompson Clinical Content is the gold standard clinical decision support protocol used by nurse triage systems worldwide for over 40 years. Being validated as 'as safe as Schmitt-Thompson' by a peer-reviewed journal is a clinical credibility statement that few digital health AI platforms can make. However the citation appears without context: a healthcare procurement manager who doesn't know what Schmitt-Thompson is receives no signal; one who does knows immediately that this is extraordinary clinical validation.
Recommendation
Add a brief context line alongside the Schmitt-Thompson citation: 'Schmitt-Thompson Clinical Content is the gold standard nurse triage protocol used worldwide for 40+ years. Peer-reviewed research in the Journal of Hospital Administration found that Infermedica performed as safely — and collected more symptom data.' This contextualisation transforms a citation that means everything to clinical informaticists and nothing to general healthcare administrators into a claim legible to both audiences. The citation currently functions as preaching to the choir; the context makes it convert.
Copy
Competitor Context — 'Performed as Safely as Schmitt-Thompson' Citation on Homepage, Not Explained
Score
48
Severity
Medium
Finding
The homepage indexed snippet includes the quote: 'In our evaluation, Infermedica performed as safely as Schmitt-Thompson. Additionally, Infermedica collects more initial patient symptoms, allowing for more data-driven assistance. — The Journal of Hospital Administration.' This citation is powerful — Schmitt-Thompson Clinical Content is the gold standard clinical decision support protocol used by nurse triage systems worldwide for over 40 years. Being validated as 'as safe as Schmitt-Thompson' by a peer-reviewed journal is a clinical credibility statement that few digital health AI platforms can make. However the citation appears without context: a healthcare procurement manager who doesn't know what Schmitt-Thompson is receives no signal; one who does knows immediately that this is extraordinary clinical validation.
Recommendation
Add a brief context line alongside the Schmitt-Thompson citation: 'Schmitt-Thompson Clinical Content is the gold standard nurse triage protocol used worldwide for 40+ years. Peer-reviewed research in the Journal of Hospital Administration found that Infermedica performed as safely — and collected more symptom data.' This contextualisation transforms a citation that means everything to clinical informaticists and nothing to general healthcare administrators into a claim legible to both audiences. The citation currently functions as preaching to the choir; the context makes it convert.
Copy
Competitor Context — 'Performed as Safely as Schmitt-Thompson' Citation on Homepage, Not Explained
Score
48
Severity
Medium
Finding
The homepage indexed snippet includes the quote: 'In our evaluation, Infermedica performed as safely as Schmitt-Thompson. Additionally, Infermedica collects more initial patient symptoms, allowing for more data-driven assistance. — The Journal of Hospital Administration.' This citation is powerful — Schmitt-Thompson Clinical Content is the gold standard clinical decision support protocol used by nurse triage systems worldwide for over 40 years. Being validated as 'as safe as Schmitt-Thompson' by a peer-reviewed journal is a clinical credibility statement that few digital health AI platforms can make. However the citation appears without context: a healthcare procurement manager who doesn't know what Schmitt-Thompson is receives no signal; one who does knows immediately that this is extraordinary clinical validation.
Recommendation
Add a brief context line alongside the Schmitt-Thompson citation: 'Schmitt-Thompson Clinical Content is the gold standard nurse triage protocol used worldwide for 40+ years. Peer-reviewed research in the Journal of Hospital Administration found that Infermedica performed as safely — and collected more symptom data.' This contextualisation transforms a citation that means everything to clinical informaticists and nothing to general healthcare administrators into a claim legible to both audiences. The citation currently functions as preaching to the choir; the context makes it convert.
Brand
One Peak Portfolio — One Peak Invested in 7 Companies in This Audit Series, But Investment Not Featured
Score
50
Severity
Low
Finding
One Peak Partners led Infermedica's $30M Series B in January 2022. One Peak's portfolio as listed in that press release includes Neo4j, DocPlanner, Spryker Systems, PandaDoc, Keepit, Cymulate, Paysend, HighQ, Quentic, Coople, DataGuard, and Brightflag — seven of which have appeared in this audit series. For healthcare procurement teams evaluating Infermedica, knowing the company is backed by One Peak (a specialist technology growth firm) provides vendor stability signals. The homepage does not appear to feature any investor logos or funding context based on the available indexed content. The Series B was in January 2022 — now four years ago, which is reasonable not to foreground — but the One Peak backing signals institutional maturity.
Recommendation
Add a minimal investor reference to the About or footer section: 'Series B-backed · Investors include One Peak Partners, EBRD, and Karma Ventures.' For health system and government procurement processes that explicitly assess vendor financial stability, this signals that Infermedica has institutional investors, enterprise-appropriate funding, and a track record that extends beyond the typical pre-revenue health AI startup. The EBRD investment specifically (European Bank for Reconstruction and Development) carries weight in European government and public health procurement contexts.
Brand
One Peak Portfolio — One Peak Invested in 7 Companies in This Audit Series, But Investment Not Featured
Score
50
Severity
Low
Finding
One Peak Partners led Infermedica's $30M Series B in January 2022. One Peak's portfolio as listed in that press release includes Neo4j, DocPlanner, Spryker Systems, PandaDoc, Keepit, Cymulate, Paysend, HighQ, Quentic, Coople, DataGuard, and Brightflag — seven of which have appeared in this audit series. For healthcare procurement teams evaluating Infermedica, knowing the company is backed by One Peak (a specialist technology growth firm) provides vendor stability signals. The homepage does not appear to feature any investor logos or funding context based on the available indexed content. The Series B was in January 2022 — now four years ago, which is reasonable not to foreground — but the One Peak backing signals institutional maturity.
Recommendation
Add a minimal investor reference to the About or footer section: 'Series B-backed · Investors include One Peak Partners, EBRD, and Karma Ventures.' For health system and government procurement processes that explicitly assess vendor financial stability, this signals that Infermedica has institutional investors, enterprise-appropriate funding, and a track record that extends beyond the typical pre-revenue health AI startup. The EBRD investment specifically (European Bank for Reconstruction and Development) carries weight in European government and public health procurement contexts.
Brand
One Peak Portfolio — One Peak Invested in 7 Companies in This Audit Series, But Investment Not Featured
Score
50
Severity
Low
Finding
One Peak Partners led Infermedica's $30M Series B in January 2022. One Peak's portfolio as listed in that press release includes Neo4j, DocPlanner, Spryker Systems, PandaDoc, Keepit, Cymulate, Paysend, HighQ, Quentic, Coople, DataGuard, and Brightflag — seven of which have appeared in this audit series. For healthcare procurement teams evaluating Infermedica, knowing the company is backed by One Peak (a specialist technology growth firm) provides vendor stability signals. The homepage does not appear to feature any investor logos or funding context based on the available indexed content. The Series B was in January 2022 — now four years ago, which is reasonable not to foreground — but the One Peak backing signals institutional maturity.
Recommendation
Add a minimal investor reference to the About or footer section: 'Series B-backed · Investors include One Peak Partners, EBRD, and Karma Ventures.' For health system and government procurement processes that explicitly assess vendor financial stability, this signals that Infermedica has institutional investors, enterprise-appropriate funding, and a track record that extends beyond the typical pre-revenue health AI startup. The EBRD investment specifically (European Bank for Reconstruction and Development) carries weight in European government and public health procurement contexts.
SEO
Health Checks Count in Meta Description References General AI Tool, Not B2B Platform
Score
46
Severity
Medium
Finding
The homepage meta description reads: 'Assess your symptoms with our AI-powered tool and receive personalized guidance on your next steps, all in just a few minutes.' This is consumer-facing copy — it addresses an individual user ('your symptoms', 'your next steps') rather than Infermedica's actual buyers: health insurance companies, hospital systems, government health services, and health tech platforms. The homepage title 'Homepage - Infermedica' is also distinctly lacking in keywords or value proposition. For a company whose revenue comes from B2B enterprise contracts with organisations like Allianz, Healthdirect, Techniker Krankenkasse, and Microsoft, the homepage meta description that appears in Google results is pitched at the wrong audience.
Recommendation
Rewrite the page title and meta description for the primary B2B buyer: 'Infermedica | AI Medical Guidance Platform for Health Systems & Insurers' as the title, and 'The Class IIb certified AI platform for symptom triage, digital intake, and care navigation — trusted by Allianz, Techniker Krankenkasse, Healthdirect, and 100+ healthcare organisations in 30+ countries.' This version: leads with the regulatory credential, names recognisable enterprise customers, quantifies scale, and speaks to the procurement decision-maker rather than the end patient.
SEO
Health Checks Count in Meta Description References General AI Tool, Not B2B Platform
Score
46
Severity
Medium
Finding
The homepage meta description reads: 'Assess your symptoms with our AI-powered tool and receive personalized guidance on your next steps, all in just a few minutes.' This is consumer-facing copy — it addresses an individual user ('your symptoms', 'your next steps') rather than Infermedica's actual buyers: health insurance companies, hospital systems, government health services, and health tech platforms. The homepage title 'Homepage - Infermedica' is also distinctly lacking in keywords or value proposition. For a company whose revenue comes from B2B enterprise contracts with organisations like Allianz, Healthdirect, Techniker Krankenkasse, and Microsoft, the homepage meta description that appears in Google results is pitched at the wrong audience.
Recommendation
Rewrite the page title and meta description for the primary B2B buyer: 'Infermedica | AI Medical Guidance Platform for Health Systems & Insurers' as the title, and 'The Class IIb certified AI platform for symptom triage, digital intake, and care navigation — trusted by Allianz, Techniker Krankenkasse, Healthdirect, and 100+ healthcare organisations in 30+ countries.' This version: leads with the regulatory credential, names recognisable enterprise customers, quantifies scale, and speaks to the procurement decision-maker rather than the end patient.
SEO
Health Checks Count in Meta Description References General AI Tool, Not B2B Platform
Score
46
Severity
Medium
Finding
The homepage meta description reads: 'Assess your symptoms with our AI-powered tool and receive personalized guidance on your next steps, all in just a few minutes.' This is consumer-facing copy — it addresses an individual user ('your symptoms', 'your next steps') rather than Infermedica's actual buyers: health insurance companies, hospital systems, government health services, and health tech platforms. The homepage title 'Homepage - Infermedica' is also distinctly lacking in keywords or value proposition. For a company whose revenue comes from B2B enterprise contracts with organisations like Allianz, Healthdirect, Techniker Krankenkasse, and Microsoft, the homepage meta description that appears in Google results is pitched at the wrong audience.
Recommendation
Rewrite the page title and meta description for the primary B2B buyer: 'Infermedica | AI Medical Guidance Platform for Health Systems & Insurers' as the title, and 'The Class IIb certified AI platform for symptom triage, digital intake, and care navigation — trusted by Allianz, Techniker Krankenkasse, Healthdirect, and 100+ healthcare organisations in 30+ countries.' This version: leads with the regulatory credential, names recognisable enterprise customers, quantifies scale, and speaks to the procurement decision-maker rather than the end patient.
Copy
Agentic AI / Conversational Triage — 2026 Product Focus Not Visible in Current Homepage Context
Score
47
Severity
Low
Finding
The 2025 year-in-review blog states: 'From a product perspective, our primary focus for 2026 will be on our Agentic AI solutions—especially focusing on the MDR certification of Conversational Triage and giving organizations the option of adding voice capabilities.' The blog describes Conversational Triage as combining LLMs with clinical medical ontologies to deliver a next-generation triage experience. This is Infermedica's primary differentiation narrative for 2026: not just a rule-based symptom checker, but a clinically validated conversational AI agent capable of agentic medical navigation. Yet the homepage meta description and available indexed content focus on the existing symptom checker rather than surfacing the 2026 Agentic AI roadmap direction.
Recommendation
Add an 'Introducing Conversational Triage' section or banner to the homepage: 'Agentic AI meets clinically validated medical guidance — Conversational Triage brings LLMs and our medical knowledge engine together for next-generation patient navigation.' This positions Infermedica ahead of the curve in the AI healthcare space: not a legacy symptom checker being retrofitted with AI, but a purpose-built clinical AI infrastructure platform now adding conversational and agentic layers. For procurement teams evaluating healthcare AI platforms for multi-year contracts, the roadmap direction is as important as current capabilities.
Copy
Agentic AI / Conversational Triage — 2026 Product Focus Not Visible in Current Homepage Context
Score
47
Severity
Low
Finding
The 2025 year-in-review blog states: 'From a product perspective, our primary focus for 2026 will be on our Agentic AI solutions—especially focusing on the MDR certification of Conversational Triage and giving organizations the option of adding voice capabilities.' The blog describes Conversational Triage as combining LLMs with clinical medical ontologies to deliver a next-generation triage experience. This is Infermedica's primary differentiation narrative for 2026: not just a rule-based symptom checker, but a clinically validated conversational AI agent capable of agentic medical navigation. Yet the homepage meta description and available indexed content focus on the existing symptom checker rather than surfacing the 2026 Agentic AI roadmap direction.
Recommendation
Add an 'Introducing Conversational Triage' section or banner to the homepage: 'Agentic AI meets clinically validated medical guidance — Conversational Triage brings LLMs and our medical knowledge engine together for next-generation patient navigation.' This positions Infermedica ahead of the curve in the AI healthcare space: not a legacy symptom checker being retrofitted with AI, but a purpose-built clinical AI infrastructure platform now adding conversational and agentic layers. For procurement teams evaluating healthcare AI platforms for multi-year contracts, the roadmap direction is as important as current capabilities.
Copy
Agentic AI / Conversational Triage — 2026 Product Focus Not Visible in Current Homepage Context
Score
47
Severity
Low
Finding
The 2025 year-in-review blog states: 'From a product perspective, our primary focus for 2026 will be on our Agentic AI solutions—especially focusing on the MDR certification of Conversational Triage and giving organizations the option of adding voice capabilities.' The blog describes Conversational Triage as combining LLMs with clinical medical ontologies to deliver a next-generation triage experience. This is Infermedica's primary differentiation narrative for 2026: not just a rule-based symptom checker, but a clinically validated conversational AI agent capable of agentic medical navigation. Yet the homepage meta description and available indexed content focus on the existing symptom checker rather than surfacing the 2026 Agentic AI roadmap direction.
Recommendation
Add an 'Introducing Conversational Triage' section or banner to the homepage: 'Agentic AI meets clinically validated medical guidance — Conversational Triage brings LLMs and our medical knowledge engine together for next-generation patient navigation.' This positions Infermedica ahead of the curve in the AI healthcare space: not a legacy symptom checker being retrofitted with AI, but a purpose-built clinical AI infrastructure platform now adding conversational and agentic layers. For procurement teams evaluating healthcare AI platforms for multi-year contracts, the roadmap direction is as important as current capabilities.
Copy
94% Accuracy Claim — Not Visible on Homepage Despite Being in Third-Party Listings
Score
50
Severity
Low
Finding
Capterra and GetApp profiles for Infermedica state 'Infermedica's solutions achieve 94% of accuracy' — a specific, quantified clinical accuracy claim. This figure does not appear in the homepage indexed content. For a medical AI platform where clinical accuracy is literally the product (patients and clinicians need to trust the triage outputs), a 94% accuracy claim — if backed by the peer-reviewed research Infermedica has published — is a homepage-level trust signal. The Journal of Hospital Administration citation ('performed as safely as Schmitt-Thompson') establishes comparative safety; a specific accuracy percentage establishes quantified clinical performance. Both belong on the homepage.
Recommendation
Surface the 94% accuracy figure on the homepage with its methodological source: '94% accuracy — validated in peer-reviewed research published in the Journal of Hospital Administration and Frontiers in Public Health.' Add the academic citations as hover/tooltip text or footnote links so that clinical informaticists and procurement teams can verify the claim directly. Unattributed accuracy claims in healthcare ('94% accurate') are easily dismissed; attributed, peer-reviewed accuracy claims are among the most powerful conversion tools available to a clinical AI company. Infermedica has the research; the homepage should surface it.
Copy
94% Accuracy Claim — Not Visible on Homepage Despite Being in Third-Party Listings
Score
50
Severity
Low
Finding
Capterra and GetApp profiles for Infermedica state 'Infermedica's solutions achieve 94% of accuracy' — a specific, quantified clinical accuracy claim. This figure does not appear in the homepage indexed content. For a medical AI platform where clinical accuracy is literally the product (patients and clinicians need to trust the triage outputs), a 94% accuracy claim — if backed by the peer-reviewed research Infermedica has published — is a homepage-level trust signal. The Journal of Hospital Administration citation ('performed as safely as Schmitt-Thompson') establishes comparative safety; a specific accuracy percentage establishes quantified clinical performance. Both belong on the homepage.
Recommendation
Surface the 94% accuracy figure on the homepage with its methodological source: '94% accuracy — validated in peer-reviewed research published in the Journal of Hospital Administration and Frontiers in Public Health.' Add the academic citations as hover/tooltip text or footnote links so that clinical informaticists and procurement teams can verify the claim directly. Unattributed accuracy claims in healthcare ('94% accurate') are easily dismissed; attributed, peer-reviewed accuracy claims are among the most powerful conversion tools available to a clinical AI company. Infermedica has the research; the homepage should surface it.
Copy
94% Accuracy Claim — Not Visible on Homepage Despite Being in Third-Party Listings
Score
50
Severity
Low
Finding
Capterra and GetApp profiles for Infermedica state 'Infermedica's solutions achieve 94% of accuracy' — a specific, quantified clinical accuracy claim. This figure does not appear in the homepage indexed content. For a medical AI platform where clinical accuracy is literally the product (patients and clinicians need to trust the triage outputs), a 94% accuracy claim — if backed by the peer-reviewed research Infermedica has published — is a homepage-level trust signal. The Journal of Hospital Administration citation ('performed as safely as Schmitt-Thompson') establishes comparative safety; a specific accuracy percentage establishes quantified clinical performance. Both belong on the homepage.
Recommendation
Surface the 94% accuracy figure on the homepage with its methodological source: '94% accuracy — validated in peer-reviewed research published in the Journal of Hospital Administration and Frontiers in Public Health.' Add the academic citations as hover/tooltip text or footnote links so that clinical informaticists and procurement teams can verify the claim directly. Unattributed accuracy claims in healthcare ('94% accurate') are easily dismissed; attributed, peer-reviewed accuracy claims are among the most powerful conversion tools available to a clinical AI company. Infermedica has the research; the homepage should surface it.
Frequently asked
What kind of companies do you work with?
We work with ambitious tech companies — typically Series A and B — at the moment where the brand and website haven't kept pace with the business.
You've found product-market fit. Now you need to look the part, communicate clearly, and move fast enough to stay ahead.
That's the problem we're built for.
What does a typical project look like?
We've had bad experiences with agencies before. What's different?
Why Framer over other platforms?
How do we get started?
How does pricing work?
Recent work
V7 Labs
Enzai
Utila
Centific
Buena
trawa
Portex Global
Othello AI
Echo
Pools
Contentcloud
Wilson
Perspectives & Insights
Blazing fast brands &
Blazing fast brands &
Blazing fast brands &
websites for startups
websites for startups
websites for startups